SUPERNUS PHARMACEUTICALS
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. The company’s extensive expertise in product development has been built over the past 20 years: initially as a stand alone development organization, then as a U.S. subsidiary of Shire plc and, upon its acquisition of substantially all the assets of Shire Laboratories Inc. in late 2005, as Supernus Pharmaceuticals.... The company is developing several product candidates in neurology and psychiatry to address large market opportunities in epilepsy, ADHD and depression. In addition to its two ADHD product candidates, Supernus is developing two late stage epilepsy product candidates, SPN-538 (extended release topiramate), and Epliga® (extended release oxcarbazepine).
SUPERNUS PHARMACEUTICALS
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2005-01-01
Address:
Rockville, Maryland, United States
Country:
United States
Website Url:
http://www.supernus.com
Total Employee:
251+
Status:
Active
Contact:
3014241385
Email Addresses:
[email protected]
Total Funding:
539.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Font Awesome Wordpress Plugins
Similar Organizations
EpiVax
EpiVax is an immunology company developing comprehensive analytical capabilities in the field of computational immunology.
Passage Bio
Passage Bio is a fully integrated gene therapy company developing therapies for the treatment of monogenic central nervous system diseases.
EyePoint Pharmaceuticals
EyePoint Pharmaceuticals specializes in the development and commercialization of ophthalmic products for the treatment of eye diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-10-11 | Adamas Pharmaceuticals | Adamas Pharmaceuticals acquired by Supernus Pharmaceuticals | 450 M USD |
| 2018-09-14 | Biscayne NeuroTherapeutics | Biscayne NeuroTherapeutics acquired by Supernus Pharmaceuticals | 185 M USD |
Investors List
New Enterprise Associates
New Enterprise Associates investment in Series A - Supernus Pharmaceuticals
OrbiMed
OrbiMed investment in Series A - Supernus Pharmaceuticals
Official Site Inspections
http://www.supernus.com Semrush global rank: 2.21 M Semrush visits lastest month: 8.85 K
- Host name: ec2-3-214-152-230.compute-1.amazonaws.com
- IP address: 3.214.152.230
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
